News - details

19 March 2004

Isogenica publishes key paper describing its proprietary CIS display in PNAS

Isogenica Ltd, Cambridge, UK today announced the publication of a paper which describes CIS display, the Company's proprietary in vitro molecular evolution technology. The paper, detailing the successful isolation of panels of fine-specificity polypeptide ligands to a series of molecular targets using CIS display, has been published in the prestigious scientific journal, Proceedings of the National Academy of Sciences, USA:

Odegrip, et al. (2004) Proc. Nat. Acad. Sci. (USA), vol 101, 2806-2810.

Isogenica’s CIS display technology is an in vitro methodology that allows the rapid construction of vast gene libraries. From these libraries, it is possible to rapidly select polypeptides that bind with high affinity and fine specificity to commercially relevant targets. The technology can be applied to the discovery and/or optimization of new antibody, peptide and polypeptide drug candidates. Furthermore, CIS-display technology can also be applied to the discovery of high-specificity diagnostic compounds and to the isolation of target validation probes, research reagents, purification reagents, and environmental detection reagents.

"PNAS is undoubtedly one of the world’s most prestigious scientific journals. It aims to publish only the top 5% of all scientific papers," said Isogenica’s CEO, Dr Kevin FitzGerald. "This publication therefore provides solid scientific validation of Isogenica’s technology adding to the commercial validation that has already been achieved through our execution of several agreements with a number of high-profile biotechnology and pharmaceutical companies".